Actively Recruiting
A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
Led by Jade Biosciences, Inc. · Updated on 2026-05-13
40
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.
CONDITIONS
Official Title
A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male or female participants aged 18 to 55 years
- First-generation Japanese or Chinese participants born in Japan or China
- Body weight between 40 and 100 kg
- Body mass index (BMI) between 18.0 and 32.0 kg/m2
- Willing and able to comply with study visits, procedures, and site stay
- Willing and able to follow contraceptive and lifestyle requirements during the study
You will not qualify if you...
- Harmful alcohol use
- Smoking, vaping, or heavy tobacco use within 2 years before screening
- Known history of illicit drug abuse
- Nursing, lactating, pregnant, or planning pregnancy during the study
- Known history of significant disease
- Known history of immunodeficiency disorder
- History of serious allergic reactions or hypersensitivity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Parexel Early Phase Clinical Unit (EPCU)
Glendale, California, United States, 91206
Actively Recruiting
Research Team
H
Han
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here